In a move that’s left many scratching their heads, a memo from the director of the FDA’s Center for Biologics Evaluation and Research has ignited a firestorm of controversy, claiming that COVID-19 vaccines “have killed American children.” Seriously? This is a bold assertion, especially when it’s based on “no fewer than 10” pediatric deaths supposedly linked to vaccination, yet details are scant.
The memo mainly points fingers at myocarditis post-vaccination but skips critical information like the children’s ages or any pre-existing health conditions. What’s more, the memo calls for stricter regulations on future vaccines. It’s like saying, “Hey, let’s make it even harder to get vaccines during pregnancy!” Oh, and don’t forget the part where it urges staff to rewrite guidance to fit the author’s “worldview.” Dissent is equated with disloyalty here—yikes! This tone is raising eyebrows, with many fearing it could stifle scientific debate.
The memo targets myocarditis but lacks vital details, pushing for stricter vaccine regulations while stifling scientific debate.
The backlash has been swift. Twelve former FDA commissioners penned a warning in the New England Journal of Medicine. They claim these assertions and proposals threaten public health. Experts are shaking their heads too, pointing out that extraordinary claims demand extraordinary evidence, which this memo lacks. Additionally, five years of evidence indicate that COVID-19 vaccines are safe for young children, further complicating the memo’s assertions.
VAERS data is cited, but it’s important to remember—it’s a passive system where anyone can submit reports. No causation is established here, folks. Critics are also worried about the memo’s potential to fuel vaccine hesitancy. If the public sees this unverified claim without context, it could lead to more people saying “no” to vaccines. Additionally, the misinterpretation of VAERS data may further exacerbate public fear regarding vaccine safety.
And let’s not forget the memo’s absence of peer-reviewed analysis. No details on timing, alternative explanations, or standardized frameworks. Just raw data thrown out there. It’s a mess. The FDA’s internal debate over how to handle this information is ongoing. The stakes are high, and the implications could impact public health security.
